Baillie Gifford & Co. Sells 630,474 Shares of Codexis, Inc. (NASDAQ:CDXS)

Baillie Gifford & Co. trimmed its holdings in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 15.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,419,093 shares of the biotechnology company's stock after selling 630,474 shares during the period. Baillie Gifford & Co. owned 4.90% of Codexis worth $10,428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of CDXS. Wells Fargo & Company MN lifted its holdings in shares of Codexis by 156.6% in the 4th quarter. Wells Fargo & Company MN now owns 6,276 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 3,830 shares during the last quarter. Captrust Financial Advisors purchased a new stake in shares of Codexis in the 2nd quarter valued at about $29,000. Quantbot Technologies LP purchased a new stake in shares of Codexis in the 1st quarter valued at about $33,000. Tower Research Capital LLC TRC lifted its holdings in shares of Codexis by 133.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,007 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 3,433 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Codexis in the 3rd quarter valued at about $42,000. 78.54% of the stock is owned by hedge funds and other institutional investors.

Codexis Price Performance

NASDAQ CDXS traded down $0.02 on Thursday, hitting $3.11. 388,850 shares of the company's stock were exchanged, compared to its average volume of 582,843. The firm's 50-day moving average price is $3.33 and its two-hundred day moving average price is $2.66. Codexis, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $4.91. The firm has a market cap of $218.63 million, a price-to-earnings ratio of -2.80 and a beta of 2.01.

Codexis (NASDAQ:CDXS - Get Free Report) last released its earnings results on Wednesday, February 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.18. Codexis had a negative return on equity of 47.58% and a negative net margin of 108.69%. The company had revenue of $26.56 million for the quarter, compared to analysts' expectations of $24.73 million. On average, research analysts predict that Codexis, Inc. will post -0.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CDXS has been the subject of several research reports. StockNews.com raised Codexis to a "sell" rating in a report on Tuesday, March 5th. Benchmark raised Codexis from a "hold" rating to a "buy" rating and set a $9.00 price objective for the company in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Codexis currently has a consensus rating of "Hold" and an average target price of $6.80.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.